A Vaginal Microbiome Pharmacology Foundation Model for Microbiome-Based Drug Development and Reproductive Health Insights
Authors:
Open Access
- 20 October 2026
- journal article
- 2026 cmbe-young-innovators
- Published by Springer Nature in Cellular and Molecular Bioengineering
- p. 1-17
Abstract
Introduction: Engineering microbiome therapies requires an organizing principle for the mechanisms by which microbiome factors impact the host. We previously developed the “pharmacobiome”, a framework that uses mechanisms of drugs to quantify the host impact of microbiome factors. Here, we generalized this framework into a Microbiome Pharmacology Foundation Model (MPFM) for mechanism-informed design of microbiome therapeutics. Methods: We used correlation analysis of vaginal multi-omics data to generate host gene signatures for vaginal microbiome factors and compared the signatures to drug treatment host transcriptomics to construct microbiome factor-drug similarity scores. This Vaginal Microbiome Pharmacology database of 6,719,800 training instances enabled us to train the MPFM, a deep autoencoder model, and to derive experimentally testable predictions of individual microbiome factors and designed combination therapeutic properties. Results: The MPFM training converged with strong performance (r = 0.57, MSE = 0.0058) and the latent space formed a continuous manifold. We analyzed cisplatin in the MPFM to identify anti-cancer metabolites and experimentally confirmed that taurine was Lactobacillus- derived and cytotoxic against cancer cell lines ( p < 0.0005). We also analyzed metronidazole to identify antibiotic metabolites and experimentally showed hydroxyisocaproate was Lactobacillus- derived and selectively killed vaginal pathogens ( p < 0.05). Finally, we used the model to explore patient-specific microbiome pharmacology and design probiotic combinations to support in vitro fertilization. Conclusions: We demonstrated consistent performance of the MPFM and experimentally supported the validity of predictions. Our continued work simulates probiotic, prebiotic, and postbiotic combinations for patient-specific in vivo sample analysis to develop tailored microbiome therapies for gynecologic conditions.Keywords
Funding Information
- National Institute of Child Health and Human Development (R01HD110367)
This publication has 49 references indexed in Scilit:
- Niclosamide as a potential antivirulence agent disrupting quorum sensing in Pseudomonas aeruginosa: A molecular and in silico approachBiochemical and Biophysical Research Communications, 2025
- Vaginal microbiota are associated with in vitro fertilization during female infertilityiMeta, 2024
- Vaginal epithelial dysfunction is mediated by the microbiome, metabolome, and mTOR signalingCell Reports, 2023
- Title: β3 Adrenergic Receptor Signaling in the Human MyometriumReproductive Sciences, 2022
- Sialic acids in gynecological cancer development and progression: Impact on diagnosis and treatmentInternational Journal of Cancer, 2021
- Vaginal microbiome: normalcy vs dysbiosisArchives of Microbiology, 2021
- Targeting the COX/mPGES-1/PGE2 Pathway in Neuroblastoma2019
- A Forward Chemical Genetic Screen Reveals Gut Microbiota Metabolites That Modulate Host PhysiologyCell, 2019
- The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to PerturbationsCell Systems, 2018
- A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 ProfilesCell, 2017